NASDAQ:ARVN Arvinas (ARVN) Stock Price, News & Analysis $6.68 -0.08 (-1.18%) As of 01:16 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Arvinas Stock (NASDAQ:ARVN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Arvinas alerts:Sign Up Key Stats Today's Range$6.52▼$6.8650-Day Range$6.41▼$8.7152-Week Range$6.33▼$14.51Volume264,419 shsAverage Volume837,769 shsMarket Capitalization$437.47 millionP/E RatioN/ADividend YieldN/APrice Target$15.18Consensus RatingModerate Buy Company Overview Arvinas, Inc. is a biotechnology company based in New Haven, Connecticut, that develops medicines using targeted protein degradation. Founded in 2013, the company applies its PROTAC technology to direct disease-related proteins for removal by the body’s natural protein-disposal system. Its research focuses primarily on cancer, including investigational therapies designed to target estrogen and androgen receptors. The company’s programs include vepdegestrant, an estrogen receptor degrader being developed with Pfizer for certain forms of breast cancer, as well as androgen receptor degraders being studied for prostate cancer. Arvinas’s drug candidates are investigational and have not all been approved for commercial use. Through research and development and collaborations with other companies, it seeks to advance targeted protein degradation as an approach to treating serious diseases.AI Generated. May Contain Errors. Read More Arvinas Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreARVN MarketRank™: 2.434865639065 of 5 starsArvinas scored higher than 49% of companies evaluated by MarketBeat, and ranked 1023rd out of 1,704 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingArvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 6 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialArvinas has a consensus price target of $15.18, representing about 126.7% upside from its current price of $6.70.Amount of Analyst CoverageArvinas has only been the subject of 3 research reports in the past 90 days.Read more about Arvinas' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Arvinas are expected to decrease in the coming year, from $0.27 to ($3.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -27.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -27.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 0.85. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.47% of the float of Arvinas has been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 7.59.Change versus previous monthShort interest in Arvinas has recently increased by 2.84%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. News and Social Media2.2 / 5News SentimentN/A News SentimentArvinas has a news sentiment score of -0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.38 average news sentiment score of Healthcare companies.Search Interest1 people have searched for ARVN on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Arvinas to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,476.00 in company stock.Percentage Held by Insiders7.30% of the stock of Arvinas is held by insiders.Percentage Held by Institutions95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arvinas' insider trading history. Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ARVN Stock News HeadlinesArvinas to Present at Jefferies Global Healthcare ConferenceNovember 11, 2026 | globenewswire.comArvinas Holding Company (ARVN) Receives a Buy from BarclaysNovember 9, 2026 | theglobeandmail.comTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Trading's Thomas Wood calls it one of the firm's most powerful proprietary trading indicators, and says the company has never run a deal like this before. There are no strings attached, just a steep Black Friday discount on a tool built for traders.November 19 at 1:00 AM | Base Camp Trading (Ad)Arvinas to Present Preliminary Clinical Data from Early Monotherapy Dose Escalation Cohorts in the Phase 1 Trial for ARV-393 (Zaloblideg), a PROTAC BCL6 Degrader, at the 2026 ...November 4, 2026 | markets.businessinsider.comArvinas (ARVN) Q3 2026 Earnings Call TranscriptNovember 3, 2026 | finance.yahoo.comArvinas Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateNovember 3, 2026 | globenewswire.comWhat To Expect From Arvinas Inc (ARVN) Q3 2026 EarningsNovember 2, 2026 | finance.yahoo.comArvinas Q3 2026 earnings previewNovember 2, 2026 | msn.comSee More Headlines ARVN Stock Analysis - Frequently Asked Questions How have ARVN shares performed this year? Arvinas' stock was trading at $11.86 at the beginning of 2026. Since then, ARVN stock has decreased by 43.5% and is now trading at $6.6960. How were Arvinas' earnings last quarter? Arvinas, Inc. (NASDAQ:ARVN) released its quarterly earnings data on Tuesday, November, 3rd. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.10. The business's revenue for the quarter was down 98.8% on a year-over-year basis. Read the conference call transcript. Is Arvinas buying back stock? Arvinas' Board of Directors approved a stock buyback plan on Wednesday, September 17th 2025, which permits the company to buy back $100 million in shares, according to EventVestor. This means that the company could reacquire up to 17.9% of its shares through open market purchases. Shares buyback plans are often a sign that the company's leadership believes its stock is undervalued. When did Arvinas IPO? Arvinas (ARVN) raised $112 million in an initial public offering on Thursday, September 27th 2018. The company issued 7,500,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO. Who are Arvinas' major shareholders? Top institutional investors of Arvinas include State Street Corp (3.17%), Goldman Sachs Group Inc. (1.23%), Algert Global LLC (0.70%) and Caxton Associates LLP (0.24%). Insiders that own company stock include John G Houston, Randy Teel, Noah Berkowitz, Andrew Saik, Sean A Cassidy, Ian Taylor, Briggs Morrison, Ronald Peck and David K Loomis. View institutional ownership trends. How do I buy shares of Arvinas? Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arvinas investors own include NVIDIA (NVDA), Tesla (TSLA), NIO (NIO), Intel (INTC), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Salesforce (CRM). Company Calendar Last Earnings11/03/2026Today11/19/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 ARVN's financial health is in the Red zone, according to TradeSmith. ARVN has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ARVN CIK1655759 Webwww.arvinas.com Phone(203) 535-1456FaxN/AEmployees246Year Founded2013Price Target and Rating Average Price Target for Arvinas$15.18 High Price Target$21.00 Low Price Target$10.00 Potential Upside/Downside+124.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($0.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$80.80 million Net Margins-3.45% Pretax Margin-3.23% Return on Equity-2.00% Return on Assets-1.43% Debt Debt-to-Equity RatioN/A Current Ratio8.39 Quick Ratio8.39 Sales & Book Value Annual Sales$262.60 million Price / Sales1.68 Cash FlowN/A Price / Cash FlowN/A Book Value$7.85 per share Price / Book0.86Miscellaneous Outstanding Shares65,490,000Free Float60,705,000Market Cap$442.38 million OptionableOptionable Beta1.81 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:ARVN) was last updated on 11/19/2026 by MarketBeat.com Staff. From Our PartnersDon’t delete this, read it todayPorter Stansberry has spent more than 30 years studying the economy and financial markets, and says he has nev...Porter & Company | SponsoredYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | Sponsored6 Men Secretly Changed America’s Money. Now It’s Happening AgainIn 1910, six powerful men secretly met to lay the groundwork for the Federal Reserve, reshaping America's fina...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arvinas With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.